We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+3.85%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$28.3M
Cap. Flow
+$26.6M
Cap. Flow %
0.86%
Top 10 Hldgs %
33.83%
Holding
206
New
17
Increased
43
Reduced
39
Closed
34

Top Buys

Rank Stock Value
1
RLYB icon
Rallybio
RLYB
+$33.8M
2
IDXX icon
Idexx Laboratories
IDXX
+$30.1M
3
GH icon
Guardant Health
GH
+$27.2M
4
AMGN icon
Amgen
AMGN
+$25.7M
5
AZN icon
AstraZeneca
AZN
+$21.2M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$35.4M
2
RMD icon
ResMed
RMD
+$33.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.9M
4
DXCM icon
DexCom
DXCM
+$20.1M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.51%
2 Real Estate 2.72%
3 Industrials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLV icon
51
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
$16.9M 0.54%
132,830
-56,100
-30% -$7.41M
WELL icon
52
Welltower
WELL
$169B
$16.7M 0.54%
203,083
– –
CRBU icon
53
Caribou Biosciences
CRBU
$145M
$15.6M 0.5%
+699,377
New +$17.1M
JAZZ icon
54
Jazz Pharmaceuticals
JAZZ
$15.9B
$14.9M 0.48%
114,059
+46,603
+69% +$7.04M
MRTX
55
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$14.8M 0.48%
83,784
– –
VTR icon
56
Ventas
VTR
$48B
$13.7M 0.44%
248,131
+40,023
+19% +$2.29M
ARWR icon
57
Arrowhead Research
ARWR
$11.9B
$12.7M 0.41%
204,214
+71,328
+54% +$4.62M
RARE icon
58
Ultragenyx Pharmaceutical
RARE
$2.45B
$12.7M 0.41%
140,726
+6,136
+5% +$555K
BHVN
59
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$12.6M 0.41%
+90,799
New +$11.3M
CVS icon
60
CVS Health
CVS
$133B
$12.5M 0.4%
147,453
– –
KRTX
61
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$12.3M 0.4%
100,458
– –
ITCI
62
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12.1M 0.39%
324,401
+121,645
+60% +$4.23M
NBIX icon
63
Neurocrine Biosciences
NBIX
$16.8B
$12M 0.38%
124,609
-88,282
-41% -$8.34M
NBP
64
NovaBridge Biosciences American Depositary Shares
NBP
$185M
$11.8M 0.38%
162,580
– –
ARGX icon
65
argenx
ARGX
$53.4B
$11.6M 0.37%
38,456
-35,954
-48% -$11.4M
ALKS icon
66
Alkermes
ALKS
$8.22B
$11.5M 0.37%
+373,824
New +$10.6M
ADPT icon
67
Adaptive Biotechnologies
ADPT
$3.59B
$11.5M 0.37%
337,722
– –
DNLI icon
68
Denali Therapeutics
DNLI
$3.65B
$11.2M 0.36%
222,420
+72,334
+48% +$4.08M
NVS icon
69
Novartis
NVS
$297B
$11.1M 0.36%
136,225
– –
IONS icon
70
Ionis Pharmaceuticals
IONS
$8.6B
$10.8M 0.35%
322,521
– –
ASND icon
71
Ascendis Pharma A/S
ASND
$16B
$10.8M 0.35%
67,794
-85,842
-56% -$11.7M
BDX icon
72
Becton Dickinson
BDX
$45.6B
$10.6M 0.34%
44,390
– –
WAT icon
73
Waters Corp
WAT
$37B
$10.2M 0.33%
28,461
-19,845
-41% -$7.77M
BMRN icon
74
BioMarin Pharmaceuticals
BMRN
$11.6B
$9.89M 0.32%
128,004
– –
ACH
75
Accendra Health
ACH
$237M
$9.23M 0.3%
294,967
+28,944
+11% +$1.14M
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Tekla Capital Management held 206 positions worth $3.11B, up 0.92% from $3.08B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Tekla Capital Management's Q3 2021 filing shows 17 new, 43 increased, 39 reduced and 34 closed positions. Its largest new stake was Rallybio: 288,584 shares worth $37.6M. The largest sale was Elevance Health, an estimated $35.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q3 2021 buy was Rallybio: 288,584 shares worth $37.6M.
  • Tekla Capital Management added most to Idexx Laboratories in Q3 2021, an estimated $30.1M increase.
  • Tekla Capital Management's biggest Q3 2021 reduction was Elevance Health, cutting an estimated $35.4M.
  • Tekla Capital Management fully exited Iovance Biotherapeutics in Q3 2021, selling an estimated $12.2M.
  • Tekla Capital Management's ten largest holdings make up 34% of its $3.11B portfolio in Q3 2021.
  • Tekla Capital Management opened 17 new positions and closed 34 in Q3 2021.
  • Tekla Capital Management's portfolio value rose 0.92% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.